Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H. Strickler, Thierry André, Kimmie Ng et al.|The Lancet Oncology|2023Cited by 244
Adherence to online monitoring of patient-reported outcomes by patients with chronic inflammatory diseases: a feasibility studyYvan Jamilloux, Collaborators, Matthieu Sarabi et al.|Lupus|2015Cited by 18